Provided by Tiger Trade Technology Pte. Ltd.

Incyte

104.40
+0.74000.71%
Post-market: 104.400.00000.00%19:34 EDT
Volume:1.67M
Turnover:174.58M
Market Cap:20.78B
PE:14.75
High:105.48
Open:104.61
Low:103.07
Close:103.66
52wk High:112.29
52wk Low:66.83
Shares:199.01M
Float Shares:163.04M
Volume Ratio:0.68
T/O Rate:1.02%
Dividend:- -
Dividend Rate:- -
EPS(TTM):7.08
EPS(LYR):6.41
ROE:30.82%
ROA:13.89%
PB:3.70
PE(LYR):16.29

Loading ...

Analysts Offer Insights on Healthcare Companies: Butterfly Network (BFLY) and Incyte (INCY)

TIPRANKS
·
8 hours ago

Analysts Have Conflicting Sentiments on These Healthcare Companies: Incyte (INCY) and Pfizer (PFE)

TIPRANKS
·
Yesterday

What Incyte (INCY)'s Oncology And Rare-Disease Pipeline Milestones Mean For Shareholders

Simply Wall St.
·
Yesterday

Incyte Corp. Stock Rises 5.5%, Outperforms Peers

Dow Jones
·
Yesterday

Incyte price target raised to $105 from $103 at Truist

TIPRANKS
·
Yesterday

Truist Securities Raises Incyte Price Target to $105 From $103, Hold Rating Kept

MT Newswires Live
·
Yesterday

BUZZ-U.S. STOCKS ON THE MOVE- Visteon, Incyte, Apogee

Reuters
·
Jun 22

BUZZ-Incyte rises as it settles Medicaid dispute with US government

Reuters
·
Jun 22

Incyte - Plans to Update Financial Guidance to Reflect Settlement Impact at Next Earnings Release - SEC Filing

THOMSON REUTERS
·
Jun 22

Incyte: Settlement Was Reached Based on the Unique Facts of Opzelura and Jakafi

THOMSON REUTERS
·
Jun 22

Incyte - CMS Will Not Apply Line Extension Regulation to Opzelura; Incyte Withdraws Lawsuit - SEC Filing

THOMSON REUTERS
·
Jun 22

Incyte - Expects One-Time Non-Cash Benefit of $246 Mln in Q2 Ending June 30, 2026 - SEC Filing

THOMSON REUTERS
·
Jun 22

Incyte - Announces Agreement With CMS to Resolve Opzelura Medicaid Rebate Litigation - SEC Filing

THOMSON REUTERS
·
Jun 22

Incyte settles CMS Opzelura Medicaid rebate dispute, drops lawsuit

Reuters
·
Jun 22

Incyte : Bmo Raises to Market Perform From Underperform; Raises Target Price to $94 From $75

THOMSON REUTERS
·
Jun 22

Incyte Raised to Market Perform From Underperform by BMO Capital

Dow Jones
·
Jun 22

BMO Capital Upgrades Incyte to Market Perform From Underperform, Adjusts PT to $94 From $75

MT Newswires Live
·
Jun 22

Incyte upgraded to Market Perform from Underperform at BMO Capital

TIPRANKS
·
Jun 22

Evan Seigerman Raises Incyte Price Target to $94 but Maintains Hold on Balanced View of Strategic Progress and Post-2029 LOE Risks

TIPRANKS
·
Jun 22

U.S. RESEARCH ROUNDUP-Baldwin Insurance Group, Diamondback Energy, Visteon

Reuters
·
Jun 22